L. Azoulay

First name
L.
Last name
Azoulay
Azoulay, L., Eberg, M., Benayoun, S., & Pollak, M. (2015). 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol. http://doi.org/10.1001/jamaoncol.2015.0387
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016). Pioglitazone use and risk of bladder cancer: population based cohort study. Bmj. http://doi.org/10.1136/bmj.i1541
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., et al. (2016). A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. N Engl J Med. http://doi.org/10.1056/NEJMoa1506115
Lian, Y., Yin, H., Pollak, M. N., Carrier, S., Platt, R. W., Suissa, S., & Azoulay, L. (2016). Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. Eur Urol. http://doi.org/10.1016/j.eururo.2016.04.035
Hicks, B. M., Yin, H., Yu, O. H., Pollak, M. N., Platt, R. W., & Azoulay, L. (2016). Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. Bmj. http://doi.org/10.1136/bmj.i5340
Klil-Drori, A. J., Tascilar, K., Yin, H., Aprikian, A., Bitton, A., & Azoulay, L. (2016). Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer. Am J Epidemiol. http://doi.org/10.1093/aje/kwv307
Klil-Drori, A. J., Yin, H., Tagalakis, V., Aprikian, A., & Azoulay, L. (2016). Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. Eur Urol. http://doi.org/10.1016/j.eururo.2015.06.022
Faillie, J. L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016). Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Intern Med. http://doi.org/10.1001/jamainternmed.2016.1531
Mandilaras, V., Bouganim, N., Yin, H., Asselah, J., & Azoulay, L. (2017). The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. Br J Cancer. http://doi.org/10.1038/bjc.2016.375
Douros, A., Yin, H., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2017). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. http://doi.org/10.2337/dc17-0595